title: Epidermal Growth Factor Receptor Inconsistency by Immunohistochemistry Method Using Different Monoclonal Antibodies in Colorectal Cancer Patients.
abstract: BACKGROUND
  Targeted therapy is typically used to treat colorectal cancer (CRC). The epidermal growth factor receptor (EGFR) was recognized as a potential therapeutic target. Does the EGFR protein express consistently using different monoclonal antibodies in clinics?
  
  
  METHODS
  One hundred and sixty-four patients (mean age 61.80 ± 12.78 years) who suffered from CRC were selected at Mackay Memorial Hospital in Taiwan. Formalin-fixed and paraffin-embedded tissue sections from all patients were tested simultaneously using two commercial antibodies, Dako-EGFR (mouse monoclonal anti-EGFR clone 2-18C9, pharmDx) and NCL-EGFR (NCL-EGFR-384, Novocastra) monoclonal antibodies, to study the commutability or equality of the qualities of EGFR expression by standard immunohistochemistry (IHC) procedures.
  
  
  RESULTS
  The EGFR expressions that were obtained by IHC staining using different monoclonal antibodies with Dako-EGFR (46.95%) and NCL-EGFR (32.32%) were fairly concordant.
  
  
  CONCLUSIONS
  Although IHC is a convenient and feasible method for detecting the expression of EGFR, it yields controversial staining results concerning EGFR expression using various commercial antibodies in a CRC tumor section.
authors.forename: Chi-Chen
authors.initials: CC
authors.lastname: Fan
authors.forename: Tao-Yeuan
authors.initials: TY
authors.lastname: Wang
authors.forename: Chien-Min
authors.initials: CM
authors.lastname: Kung
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology*; D015179:Colorectal Neoplasms / Q000276:immunology / Q000378:metabolism*; D066246:ErbB Receptors / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D013624:Taiwan
chemical_list: D000911:Antibodies, Monoclonal; D066246:ErbB Receptors